肝癌における遺伝子変異について｜ざいつ内科クリニック｜山口市小郡の一般内科、血液内科、アレルギー科

肝癌における遺伝子変異について

分子標的薬を設計するとき、当然特異的な酵素をターゲットに考えるべきで報告があるものを載せました。

Chromosome	Type of aberration	Targeted genes	Correlations with clinical and pathological parameters	Ref.
1q21	Gain	CHD1L, CKS1B, JTB, SHC1	Progression of HCC	Hyeon et al[43]
1q21-23	Gain	-	Early development	Yim et al[40]
1q21-q22	Gain	-	Metastasis	Wang et al[41]
1q21.1-q23.2	Gain	BCL9, ARNT, TPM3, MUC1, NTRK1	Poorly differentiated HCV-associated HCC	Liu et al[42]
1q22-23.1	Gain	CD1d	Diagnosis and prognosis	Zhang et al[44]
1q24.1-24.2	Gain	MPZL1	Intrahepatic metastasis	Jia et al[45]
8q24.21-24.22	Gain	MYC, DDEF1, MLZE	Prognosis (DFS and OS)	Pedica et al[47]
8q21.13	Gain	HEY1	Proliferation	Jia et al[37]
8q22.3	Gain	CTHRC1	Aggressive HCC	Tameda et al[48]
8q24.3	Gain	BOP1	Advanced-stage HCC, microvascular invasion and shorter DFS	Chung et al[50]
7q21.3	Gain	SGCE, DYNC1I1, PEG10	Hepatocarcinogenesis	Tsuji et al[51]
4q34.3-35	LOH	ING2	Progression	Zhang et al[56]
4q13.3-q35.2	LOH	ADH4, ADH1C, ADH1A, ADH6	HBV- and AFB1-related HCC carcinogenesis	Qi et al[58]
8p	LOH	DLC1, CCDC25, ELP3, PROSC, SH2D4A, SORBS3	Early stage of hepatocarcinogenesis, poor outcomes	Tornillo et al[59]; Roessler et al[30]
8p22-p23	LOH	MCPH1, KIAA1456, TUSC3, ZDHHC2	Metastasis and prognosis	Peng et al[62]
D4S2964	LOH	ARD1B, SEPT11	Prognosis (OS)	Huang et al[63]
6q26-q27	LOH	M6P/IGF2R	Poor outcomes	Jang et al[64]